sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
klertis 50 mg
egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica
klertis 25 mg
egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica
klertis 12,5 mg
egis pharmaceuticals plc, maďarsko - sunitinib - 44 - cytostatica
sunitinib glenmark 50 mg tvrdé kapsuly
glenmark pharmaceuticals s.r.o., Česká republika - sunitinib - 44 - cytostatica
sunitinib glenmark 37,5 mg tvrdé kapsuly
glenmark pharmaceuticals s.r.o., Česká republika - sunitinib - 44 - cytostatica
sunitinib glenmark 25 mg tvrdé kapsuly
glenmark pharmaceuticals s.r.o., Česká republika - sunitinib - 44 - cytostatica
sunitinib glenmark 12,5 mg tvrdé kapsuly
glenmark pharmaceuticals s.r.o., Česká republika - sunitinib - 44 - cytostatica
sunitinib pharmagen 50 mg
pharmagen cz s.r.o., Česká republika - sunitinib - 44 - cytostatica
sunitinib pharmagen 25 mg
pharmagen cz s.r.o., Česká republika - sunitinib - 44 - cytostatica